Vogt M W, Hartshorn K L, Furman P A, Chou T C, Fyfe J A, Coleman L A, Crumpacker C, Schooley R T, Hirsch M S
Science. 1987 Mar 13;235(4794):1376-9. doi: 10.1126/science.2435003.
Azidothymidine and ribavirin both inhibit replication of human immunodeficiency virus in vitro and show promise of clinical utility in patients infected with this virus. In this study, the possible interactions of these drugs were examined in vitro, and a reproducible antagonism between azidothymidine and ribavirin was found to occur under a variety of experimental conditions. The mechanism responsible for this antagonism appeared to be inhibition of azidothymidine phosphorylation by ribavirin. Because similar effects may occur in vivo, clinical trials of these two drugs in combination must be performed only under carefully controlled conditions.
叠氮胸苷和利巴韦林在体外均能抑制人类免疫缺陷病毒的复制，并显示出对感染该病毒患者的临床应用前景。在本研究中，对这些药物可能的相互作用进行了体外研究，发现在多种实验条件下，叠氮胸苷和利巴韦林之间会出现可重复的拮抗作用。这种拮抗作用的机制似乎是利巴韦林抑制了叠氮胸苷的磷酸化。由于体内可能会出现类似效应，因此这两种药物联合使用的临床试验必须仅在严格控制的条件下进行。
